Brian O Mahony/ X
Jul 13, 2026, 19:47
Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
Brian O Mahony, CEO of Irish Haemophilia Society, shared a post on X:
“Feng Xue on BBM-H901 at ISTH 2026, FIX Gene therapy developed in China.
Approved in China April 2025.
Mean FIX expression after 2 years 61% Distribution :
- 76% FIX more than 40 ,
- 20% FIX less than 40,
- 10% FIX less than 20,
- 5% FIX less than 10,
- 2% FIX less than 2″
Other posts featuring Brian O Mahony on Hemostasis Today
-
Aug 29, 2026, 17:05What If Factor XI inhibition Could Reshape the Future of Anticoagulation – ISTH
-
Aug 29, 2026, 16:44Nipocalimab for Warm Autoimmune Hemolytic Anemia: What the FDA Approval Means
-
Aug 29, 2026, 16:17The Future of Bleeding Disorder Research is Getting Bigger – Global Hemophilia Report
-
Aug 29, 2026, 16:03Marco De Giovanni: The Platelet – Serotonin Link Behind Severe COVID-19
-
Aug 29, 2026, 16:01FDA Approves Imaavy for wAIHA – Thalassaemia International Federation
-
Aug 29, 2026, 16:00Dianne E. van der Wal: Advancing Platelet Research at ISTH 2026 in Paris
-
Aug 29, 2026, 15:55Cory Dugan: Iron Deficiency and Anemia Across the Female Life
-
Aug 29, 2026, 15:53Melina Rodriguez: FDA Approves Imaavy as First Treatment for Warm AIHA
-
Aug 29, 2026, 15:50Karen T․: Seeking a Patient Liaison to Support the Bleeding Disorders Community